AI Article Synopsis
Article Abstract
Background And Aims: Helicobacter pylori (H. pylori) eradication in patients who failed one or more therapeutic attempts remains challenging. This study aimed to assess the efficacy of three-in-one capsules bismuth-based quadruple therapy (Pylera®) in these patients managed in clinical practice.
Methods: This was a prospective, open-label, multicenter study enrolling consecutive, adult patients with persistent H. pylori infection following at least one standard therapy. All patients received a rescue quadruple therapy with Pylera (3 capsules four times daily) and esomeprazole 20 mg (1 tablet twice daily) for 10 days. H. pylori eradication was assessed by using Urea Breath Test 4-6 weeks following therapy ending. H. pylori eradication rates, compliance, and side-effects were calculated.
Results: A total of 208 patients in the 9 participating centres were enrolled. Overall, 180 patients were successfully cured from the infection, accounting for 86.5% (95% CI 81.9-91.2) and 92.3% (95% CI 88.6-96.1) eradication rates at intention-to-treat analysis and at per protocol analysis, respectively. Cure rates were similar across patients who failed one to three previous therapy attempts, but the success rate fell to 67% after 4 or more therapy failures. Compliance to therapy was good in 198 (95.2%) patients, whilst in 7 (5.3%) cases the therapy was interrupted within 5 days due to side effects. A total of 97 (46.6%) patients complained of at least one side effect; nausea, diarrhea and vomiting were the most frequently reported.
Conclusions: Our study found that this bismuth-based quadruple therapy is highly effective as second-line and rescue therapy for H. pylori eradication in clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.15403/jgld.2014.1121.263.zul | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Eradication of Helicobacter pylori by a potassium-competitive acid blocker alone?
Scand J Gastroenterol
December 2024
Department of clinical and molecular medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Aims: , the dominating cause of gastric cancer, most often infects children initiating inflammation in the antral part and spreads orally to the oxyntic mucosa. Traditionally, eradication of has been based upon a combination of antibiotics together with a proton pump inhibitor (PPI) to reduce gastric destruction of the antibiotics. Recently it has been shown that the more efficient inhibitors of acid secretion, the potassium-competitive acid blockers (PCABs) in combination with amoxicillin alone gave highly sufficient eradication.
View Article and Find Full Text PDFEfficacy of Lactobacillus spp. Supplementation in Helicobacter pylori Eradication: A Systematic Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis.
Helicobacter
December 2024
Department of Biotechnology, Berhampur University, Berhampur, Odisha, India.
Background: Helicobacter pylori infection is a major global health concern and has been associated with a number of gastrointestinal disorders. Probiotics, especially Lactobacillus spp., have been suggested to have beneficial effect in managing H.
View Article and Find Full Text PDFAGA Clinical Practice Update on Screening and Surveillance in Individuals at Increased Risk for Gastric Cancer in the United States: Expert Review.
Gastroenterology
December 2024
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, California.
Description: Gastric cancer (GC) is a leading cause of preventable cancer and mortality in certain US populations. The most impactful way to reduce GC mortality is via primary prevention, namely Helicobacter pylori eradication, and secondary prevention, namely endoscopic screening and surveillance of precancerous conditions, such as gastric intestinal metaplasia (GIM). An emerging body of evidence supports the possible impact of these strategies on GC incidence and mortality in identifiable high-risk populations in the United States.
View Article and Find Full Text PDF[Characteristics of Gastric Mucosa-associated Lymphoid Tissue Lymphoma in Korea].
Korean J Gastroenterol
December 2024
Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
The prevalence of gastric mucosa-associated lymphoid tissue (MALT) lymphoma in Korea has not been reported largely because, it is a relatively rare disease. Gastric MALT lymphoma is clinically important because of the high prevalence of () in Korea. The endoscopic findings of gastric MALT lymphoma are diverse, and it is often challenging to differentiate from gastric adenocarcinoma.
View Article and Find Full Text PDFPrevalence and associated risk factors of infection in community households in Lanzhou city.
World J Gastroenterol
December 2024
Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China.
Background: () infection exhibits a familial clustering phenomenon.
Aim: To investigate the prevalence of infection, identify associated factors, and analyze patterns of transmission within families residing in the community.
Methods: From July 2021 to September 2021, a total of 191 families (519 people) in two randomly chosen community health service centers in the Chengguan District of Lanzhou in Gansu Province, were recruited to fill out questionnaires and tested for infection.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!